Sorafenib for advanced and refractory desmoid tumors

Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert M. Conry, Sujana Movva, Michael J. Pishvaian, Richard F. Riedel, Tarek Sabagh, William D. Tap, Natally Horvat, Ethan Basch, Lawrence H. Schwartz, Robert G. Maki, Narasimhan P. Agaram, Robert A. LefkowitzYousef Mazaheri, Rikiya Yamashita, John J. Wright, Amylou C. Dueck, Gary K. Schwartz

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

BACKGROUND Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care. METHODS In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400- mg tablet once daily) or matching placebo. Crossover to the sorafenib group was permitted for patients in the placebo group who had disease progression. The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated. RESULTS With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group. The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group. The objective responses are ongoing. Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%). CONCLUSIONS Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses.

Original languageEnglish (US)
Pages (from-to)2417-2428
Number of pages12
JournalNew England Journal of Medicine
Volume379
Issue number25
DOIs
StatePublished - Dec 20 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sorafenib for advanced and refractory desmoid tumors'. Together they form a unique fingerprint.

  • Cite this

    Gounder, M. M., Mahoney, M. R., Van Tine, B. A., Ravi, V., Attia, S., Deshpande, H. A., Gupta, A. A., Milhem, M. M., Conry, R. M., Movva, S., Pishvaian, M. J., Riedel, R. F., Sabagh, T., Tap, W. D., Horvat, N., Basch, E., Schwartz, L. H., Maki, R. G., Agaram, N. P., ... Schwartz, G. K. (2018). Sorafenib for advanced and refractory desmoid tumors. New England Journal of Medicine, 379(25), 2417-2428. https://doi.org/10.1056/NEJMoa1805052